Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development

January 9, 2023

New, two-chip, single-cell optofluidic system ideal for small- to mid-sized biopharma & CDMOs/CROs to affordably gain access to the Beacon® technology and cell line development-specific applications

EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced the launch of the Beacon Select, the company's new optofluidic system for cell line development (CLD). The Beacon Select builds upon the same cutting-edge technology offered by the original Beacon system launched in 2017 that currently has an installed base of more than 130 systems globally. The Beacon Select offers customers optofluidic and NanoPen® chamber technology and propriety CLD applications, but with the optimum level of features to meet the research and budgetary needs for new market segment customers.

Beacon Select is a two-chip, single-cell optofluidic system for CLD that enables scientists to clone, culture, assay and select top clones in a single run on a single platform and ideally suited for small- to mid-sized biopharma and CDMOs/CROs. This contrasts with the initial four-chip Beacon system enabled for antibody discovery and CLD, geared toward high-campaign usage from large biopharma and established CDMOs/CROs. The Beacon Select enables high throughput cloning, screening, and selection of top-performing CHO cell lines in just days using the Opto® CLD workflow. In addition, the Opto® Assure Assays enable users to select clones with favorable product quality attributes within five days of cloning to reduce overall bioprocessing costs, improve the probability of success, and further shorten timelines by selecting higher quality clones for scale up.

To increase customer accessibility and affordability, Berkeley Lights will offer Beacon Select with different purchase options including capital placement, lease, or reagent rental. The two-chip Beacon Select list price will be approximately half of the current Beacon system, which makes the technology ideal for new users that do not need the full Beacon capacity. In addition, this lower price point allows existing CLD Beacon customers to increase throughput and existing Antibody Discovery Beacon customers to access CLD applications.

"Berkeley Lights is enhancing its approach to the market with the introduction of a more flexible configuration and pricing models that is focused on customers' total cost of ownership," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights. "The Beacon Select is the first in a series of new platform launches that provide lower barriers to entry for customers to acquire our game-changing technology focused on cell line development. By the second half of 2023, we will also offer Beacon Quest an optofluidic system specialized for academic research institutes and translational research centers."

Additional Features and Benefits of the Beacon Select

The Beacon Select system can:

  • Select clones with higher titers than traditional methods
  • Increase throughput by 2x while reducing cell line development timelines by up to 50%
  • Achieve cloning efficiencies 5x greater than FACS and 10x greater than limiting dilution, while recovering clones with >99% monoclonality assurance
  • Utilize the new Berkeley Lights' Custom Productivity Assay that enables selection of clones secreting a wide variety of molecules, including antibodies, protein-based vaccines, enzymes, fusion proteins, antibody fragments, and cytokines. This capability allows a wide variety of projects to be completed on a single instrument.

For more information about the Beacon Select, please visit our website:

About Berkeley Lights

Berkeley Lights is a life sciences tools company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect® chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Forward-Looking Statements 

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to actual results, customer receptivity and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's products, sales, market strategy, growth and continual evolution, see the statements in the "Risk Factors" sections and elsewhere in our filings with the U.S. Securities and Exchange Commission.

Cision View original content to download multimedia:

SOURCE Berkeley Lights, Inc.